- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2005
OCCULOGIX, INC.
(Exact name of Registrant as specified in its Charter)
Delaware 000 51030 59-343-4771
(State or other Jurisdiction) (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
2600 Skymark Avenue, Unit 9, Suite 201
Mississauga, Ontario L4W 5B2
(Address of principal executive offices)
Registrant's telephone number, including area code: (905) 602-0887
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
- --------------------------------------------------------------------------------
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
This is an amendment to Item 1.01 of the Form 8-K filed on May 20, 2005.
The Company entered into a settlement agreement, dated as of May 20, 2005, with
Dr. David Craig Eldridge, O.D. and David C. Eldridge O.D., P.C. ("Eldridge
P.C."), Dr. Eldridge's professional corporation. Dr. Eldridge is currently the
Company's Vice President, Science and Technology. Under the terms of the
settlement agreement, the Company will pay $48,000 to Eldridge P.C. in
settlement of a dispute between Dr. Eldridge and the Company relating to the
equity portion of consideration payable by Vascular Sciences Corporation (now
the Company) to Dr. Eldridge under a consulting agreement. Dr. Eldridge
continues to be employed by the Company as Vice President, Science and
Technology.
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS
This is an amendment to Item 5.02 of the Form 8-K filed on May 20, 2005.
On May 19, 2005, the Company issued a press release announcing the appointment
of John Y. Caloz, age 52, as the Company's Chief Financial Officer and
Treasurer, which appointment will be effective June 1, 2005. Mr. Caloz will
succeed William G. Dumencu who will remain with the Company as VP, Finance.
Pursuant to the terms of his employment agreement with the Company, dated as of
May 18, 2005, Mr. Caloz will serve the Company in the position of Chief
Financial Officer and Treasurer for an indefinite term beginning on June 1,
2005. Mr. Caloz's compensation will consist of a gross salary of Cdn.$240,000
per annum, annual bonus remuneration in the amount of 50% of his gross salary
based upon attainment of performance criteria (with a guaranteed minimum bonus
payment in the first year of employment of 20% of his annual gross salary, pro
rated to the effective date of his appointment), time-based options under the
Company's 2002 Stock Option Plan to purchase 100,000 common shares and
performance-based options under the Company's 2002 Stock Option Plan to purchase
62,500 common shares.
-3-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
OCCULOGIX, INC.
Date: May 20, 2005
By: /s/Stephen Kilmer
---------------------------------
Stephen Kilmer
Vice President, Corporate Affairs